Covered recipient · General Payments record
ANH TONNU
Eye and Vision Services Providers Optometrist
General Payments · PY2019–2024
$2,505.59
- Reported across 55 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $629.03 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Bausch & Lomb Americas Inc. | $187.05 | 3 |
| Amgen Inc. | $141.72 | 8 |
| Dompe US, Inc. | $131.71 | 1 |
| CooperVision Inc. | $73.38 | 1 |
| Gilead Sciences, Inc. | $41.12 | 2 |
| Tarsus Pharmaceuticals, Inc. | $39.63 | 1 |
| ABBVIE INC. | $14.42 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.42 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106232239 | CMS |
| Amgen Inc. | $5.60 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111726183 | CMS |
| Amgen Inc. | $18.21 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111726185 | CMS |
| Amgen Inc. | $1.82 | 07/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111726187 | CMS |
| Amgen Inc. | $20.89 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111726189 | CMS |
| Amgen Inc. | $24.69 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111726191 | CMS |
| Amgen Inc. | $27.90 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111726193 | CMS |
| Amgen Inc. | $25.36 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111726195 | CMS |
| Amgen Inc. | $17.25 | 10/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111726197 | CMS |
| Bausch & Lomb Americas Inc. | $140.92 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140302812 | CMS |
| Bausch & Lomb Americas Inc. | $24.74 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140302808 | CMS |
| Bausch & Lomb Americas Inc. | $21.39 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140302810 | CMS |
| CooperVision Inc. | $73.38 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145511536 | CMS |
| Dompe US, Inc. | $131.71 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151397421 | CMS |
| Gilead Sciences, Inc. | $21.43 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133632192 | CMS |
| Gilead Sciences, Inc. | $19.69 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133632194 | CMS |
| Tarsus Pharmaceuticals, Inc. | $39.63 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139137100 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.